TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: EVL (Endoscopic Variceal Ligation) Plus Vasoconstrictor vs.Ligation Plus PPI( Proton Pump Inhibitor) in the Control of Acute Esophageal Variceal Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The etiology of portal hypertension is cirrhosis.~* Age ranges between 18-80 y/o.~* Patients presenting with acute esophageal variceal bleeding proven by emergency endoscopy within 12 hours. (Acute esophageal variceal bleeding was defined as: (1) when blood was directly seen by endoscopy to issue from an esophageal varix (active bleeding), or (2) when patients presented with red color signs on their esophageal varices with blood in esophagus or stomach and no other potential site of bleeding identified (inactive bleeding).~* EVL is performed after confirmation of acute esophageal variceal bleeding. Enrollment time: Immediately after EVL is completed and variceal bleeding is arrested.~Exclusion Criteria:~* Association with severe systemic illness, such as sepsis, COPD, uremia~* Association with gastric variceal bleeding~* Failure in the control of bleeding by emergency EVL~* Moribund patients, died within 12 hours of enrollment~* Uncooperative~* Ever received EIS, EVL within one month prior to index bleeding~* Child-Pugh's scores \> 13

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EVL + vasoconstrictor (Type: ACTIVE_COMPARATOR): Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
- EVL + PPI (Type: EXPERIMENTAL): Pantoloc 40 mg intravenously per day was instituted on enrollment and continued for 5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-79 years~* Stable does of statins ≥ 8 weeks prior to screening~* Good health by medical history, physical exam, electrocardiogram, laboratory test (e.g., serum chem., urinalysis)~* Mean fasting serum triglyceride of two most recent tests in medical record ≥ 200 and \< 500 mg/dL~* Mean LDL-cholesterol of two most recent tests in medical record ≤ 1.1 × NCEP ATP III goal~Exclusion Criteria:~* Medications, vitamin pills, nutritional supplements or herbal preparations deemed exclusionary per primary investigator for possible interference~* Poorly controlled diabetes mellitus (e.g. \[HbA1c\] \> 8.0%)~* History of a cardiovascular event~* Past revascularization procedure~* Past aortic aneurysm or an aortic dissection \< 6 months prior to screening~* History of pancreatitis~* Sensitivity to any statin OR to omega-3 fatty acids or fish products~* Poorly controlled hypertension (i.e.: \>=160 systolic (resting) and/or \>=100 diastolic (resting)) at 2 consecutive visits~* Serum Creatinine ≥ 2.0 mg/dL~* Serum transaminase \> 1.5 × upper limit of normal (ULN); including aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\]; 31 U/L for AST, 45 U/L for ALT~* Creatine Kinase (CK) \> 3.0 × ULN~* Taking other triglyceride lowering drugs (e.g., niacin, fibrates) or fish oil supplements providing more than 500 mg of EPA+DHA per day~* Contraindications for Lovaza per product insert~* Women who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Lovaza (Type: EXPERIMENTAL): Lovaza was given as the only agent; there was no comparator agent or arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* microscopy confirmed P. vivax mono-infection~* age \>2 years~* weight \>5kg~* \>1 asexual parasite per 10 fields~Exclusion Criteria:~* pregnant~* evidence of concomitant infection or serious disease~* recent use of antimalarial drugs~* severe malaria~* known allergy to study drugs

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: tDCS for Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic Low Back Pain ≥ 6 months duration in the lumbar region, present more than half the days of the month, and on average be at a moderate level of severity in the last month~* At least one trial of physician recommended medication (e.g. acetaminophen, NSAIDS, skeletal muscle relaxants)~* Pre-existing opioid and non-opioid pain medication must be non-existent or stable (medications have not changed for one month)~* Be able to understand, read and write English~* If female and of childbearing age, agree to use acceptable birth control during the study treatment period (oral contraceptives, history of tubal ligation, history of a hysterectomy, or a reliable barrier method)~Exclusion Criteria:~* Lifetime Diagnostic and Statistical Manual (DSM) IV diagnosis of bipolar disorder, schizophrenia, or other chronic psychotic condition~* Current DSM-IV diagnosis of substance dependence for alcohol, sedative/hypnotic drugs, stimulants, cocaine~* Current cancer, infection, or inflammatory arthritis~* Broken skin or other lesions in the area of the electrodes~* Uncontrolled medical problems, such as diabetes mellitus, hypertension, pulmonary or airway disease, heart failure, coronary artery disease, or any other condition that poses a risk for the subject during participation~* Presence of metal in the cranial cavity~* Holes in the skull made by trauma or surgery~* Pacemakers, medication pumps, and other implanted electronic hardware~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sham tDCS (Type: SHAM_COMPARATOR): 10 sessions sham transcranial direct current stimulation (tDCS)
- active tDCS (Type: EXPERIMENTAL): 10 sessions active transcranial direct current stimulation (tDCS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ESP in Breast Surgery Due to Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Elective surgery of breast due to cancer~* obtained consent~Exclusion Criteria:~* the lack of consent~* the surgery of two breasts~* reoperation of the same breast~* previous participation in the study~* coagulopathy~* allergy to morphine and local anesthetics~* depression, antidepressant drugs treatment~* epilepsy~* usage of painkiller before surgery~* addiction to alcohol or recreational drugs

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Controlled (Type: PLACEBO_COMPARATOR): Standard care without regional block. General anesthesia. After the end of the surgery, the patient-controlled analgesia with oxycodone.
- ESP block (Type: EXPERIMENTAL): After the induction of general anesthesia, before the beginning of the surgery, the erector spinae plane block with 0.375% ropivacaine will be performed. Then, the patient will be treated as in the controlled group.
- Sham block (Type: SHAM_COMPARATOR): After the induction of general anesthesia, before the beginning of the surgery, the erector spinae plane block with 0.9% saline will be performed. Then, the patient will be treated as in the controlled group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven Hodgkin's disease No more than 5 weeks since diagnostic biopsy No B symptoms Clinical/pathologic stages (all histologies) as follows: Stage IA/IIA with mediastinal mass less than one third of chest diameter Stage IIIA limited to spleen or splenic, celiac, or portal nodes and lesions no larger than 6 cm Surgical staging required if: Clinical and imaging findings equivocal Tanner stage IV/V for whom radiotherapy is planned Concurrent registration on protocols POG-8828 (late effects study) and POG- 8829 (epidemiology study) required~PATIENT CHARACTERISTICS: Age: 21 and under Performance status: Not specified Hematopoietic: No hematopoietic disease Hepatic: No liver disease Renal: No renal disease Other: No severe organ or system damage or failure No pregnant or nursing women~PRIOR CONCURRENT THERAPY: No prior therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Treatment #1 (Without Zinecard) (Type: EXPERIMENTAL): All patients undergoing a splenectomy must receive penicillin or erythromycin prophylaxis twice a day. Pneumocystis prophylaxis:TMP/SMZ 150mg/m2(maximum 300 mg) of TMP in 2 divided doses on 3 consecutive days each week. Aerosolized Pentamidine (200mg/m2/dose - maximum dose 300 mg) should be substituted monthly for patients who cannot tolerate TMP/SMZ therapy. Continue pneumocystis prophylaxis for 6 months after stopping therapy.~Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Bleomycin sulfate 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Vincristine sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15 Etoposide 10mg/m2/day 1-5. IV drip ( \< 0.4mg/ml) over 1 hour. Monitor blood pressure every 15 minutes during infusion. G-CSF (filgrastim) 5 mcg/Kg/day start on day 6 (24-36 hrs after 5th dose of VP16) and continued through day 13 (total 8 days).
- Treatment #2 (with Zinecard) (Type: EXPERIMENTAL): Zinecard (DZR) 250 mg/m2 IV push on days 1 and 15 before administration of doxorubicin and bleomycin sulfate. Give bleomycin sulfate and doxorubicin within 30 minutes of Zinecard (dexrazoxane hydrochloride). Bleomycin 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Vincristine Sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Current primary PTSD diagnosis based on DSM-IV criteria, with a minimum duration of 12 weeks since the traumatic event.~2. Between the age of 18 and 65.~Exclusion Criteria:~1. Current diagnosis of schizophrenia, delusional disorder, or organic mental disorder as defined by the DSM-IV.~2. Current diagnosis of bipolar disorder, depression with psychotic features, or depression severe enough to require immediate psychiatric treatment (i.e., serious suicide risk with intent and plan).~3. Current diagnosis of alcohol or substance dependence within the 3 previous months.~4. Unwilling or unable to discontinue current trauma-focused psychotherapy or psychotropic medication (at least 1 month medication free).~5. Ongoing intimate relationship with the perpetrator (in assault-related PTSD cases).~6. Unstable cardiovascular, autoimmune, endocrine, neurological, renal, hepatic, retinal, gastrointestinal, or hematological disorder or current seizure disorder.~7. Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception for the duration of active treatment.~8. A history of hypersensitivity or allergy to MB.~9. Any condition possibly affecting drug absorption (e.g., gastrectomy).~10. Glucose-6-phosphate dehydrogenase deficiency.~11. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that, in the judgment of the Medical Directors, would make the participant inappropriate for entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Psychotherapy plus Methylene Blue, USP (Type: EXPERIMENTAL): None
- Psychotherapy Plus Placebo (Type: PLACEBO_COMPARATOR): None
- Delayed Psychotherapy (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with β-thalassemia major or Diamond-Blackfan anemia (DBA) or congenital sideroblastic anemia on chronic transfusion therapy~* Myocardial T2\* value that is ≥ 5 and \< 10 ms~* Left ventricular ejection fraction (LVEF) ≥ 56% as determined by Magnetic resonance imaging (MRI)~* Liver Iron Concentration (LIC) ≥ 7 mg Fe /g dw as determined by R2 MRI.~* Lifetime history of at least 50 units of red blood cell transfusions, and must be receiving at least ≥ 8 units/yr of red blood cell transfusions~* Serum ferritin ≥ 1000 ng/mL~Exclusion Criteria:~* Patients with clinical symptoms of cardiac dysfunction (shortness of breath at rest or exertion, orthopnea, exercise intolerance, lower extremity edema, arrhythmias)~* Patients unable to undergo study assessments including MRI~* Patients with serum creatinine greater than Upper limit of normal ULN)range or with significant proteinuria as indicated by a urinary protein/creatinine ratio (UPCR) ≥1.0 mg/mg in a non-first void urine sample at baseline.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox (Type: EXPERIMENTAL): Deferoxamine combination followed by Deferasirox monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female subjects aged from 18 to 45 years inclusive at the date of informed consent.~* A history of active and regular menstrual cycles of 21 to 35 days (inclusive) in the 6 months prior to the screening visit.~* A diagnosis of endometriosis, confirmed by laparoscopy or laparotomy within10 years prior to the screening visit.~* Requires treatment with a Gonadotrophin releasing hormone (GnRH) agonist for a period of 6 months in the judgement of the investigator.~Exclusion Criteria:~* A current history of undiagnosed abnormal genital bleeding.~* Received treatment with a GnRH agonist within 6 months prior to the screening visit.~* Received any other hormonal treatment within 3 months prior to the screening visit (oestrogens, progestogens, danazol, gestrinone and cyproterone acetate etc).~* Chronic pelvic pain that is not caused by endometriosis, that would interfere with the assessment of endometriosis-associated pelvic pain.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Triptorelin pamoate PR 3-month (Type: EXPERIMENTAL): Subjects received 15 mg triptorelin pamoate per injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections, at baseline and Week 12).
- Triptorelin acetate PR 1-month (Type: ACTIVE_COMPARATOR): Subjects received 3.75 mg triptorelin acetate per injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections, at baseline and Weeks 4, 8, 12, 16 and 20).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Has met diagnostic criteria for HSDD for at least 6 months~* Is willing and able to understand and comply with all study requirements~* Has a normal pelvic examination at screening~Main Exclusion Criteria:~* Subjects should be generally healthy premenopausal females with no psychological, gynecological or urological conditions which might contribute to the sexual dysfunction, compromise study participation, or confound interpretation of the study results~* Not currently under treatment for the sexual dysfunction and willing to forego other treatments through the course of the clinical trial

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bremelanotide (BMT/BMT) (Type: EXPERIMENTAL): (Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks~(OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks
- Placebo (PBO/BMT) (Type: PLACEBO_COMPARATOR): (Main Study) PBO administered SC on an as-desired basis for 24 weeks~(OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes (diagnosed clinically) for 24 weeks or longer prior to randomisation (visit 2)~* Insulin naïve subjects (Allowed are: Previous short term insulin treatment no longer than or equal to 14 days in total; Treatment during hospitalisation or during gestational diabetes is allowed for periods longer than 14 days in total)~* Current treatment: Metformin alone or metformin in any combination of 1 or 2 additional OADs (oral anti-diabetic drug) including an insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV) inhibitors, alpha-glucosidase inhibitors or thiazolidinediones (TZDs) - all with unchanged dosing for at least 12 weeks prior to randomisation (visit 2). Metformin dose, alone or in combination (including fixed combination), must be at least 1000 mg daily~* HbA1c (glycosylated haemoglobin) 7.0-10.0% (both inclusive)~* BMI (Body Mass Index) below or equal to 45 kg/m\^2~* Ability and willingness to adhere to the protocol including self measurement of plasma glucose~Exclusion Criteria:~* Treatment with GLP-1 (glucagon like peptide) receptor agonists within the last 12 weeks prior to randomisation (visit 2)~* Recurrent severe hypoglycaemia (more than one severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the Investigator (trial physician)~* Previous participation in this trial. Participation is defined as randomised. Re-screening is allowed once during the recruitment period~* Known or suspected hypersensitivity to trial products or related products~* The receipt of any investigational drug within 4 weeks prior to randomisation (visit 2)~* Anticipated significant lifestyle changes during the study, e.g. shift work (including permanent night/evening shift workers) as well as highly variable eating habits

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDegAsp Simple (Type: EXPERIMENTAL): None
- IDegAsp Step wise (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete